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Phenylalamne ammoma-lyase lmmoblhzed wlthm semipermeable mlcrocapsules has an assayed enzyme ac- 
tlvlty whxh IS 20% + 4% of the enzyme m free solution The K, for the lmmoblhzed enzyme remamed the 
same as that of the free enzyme The pH optimum also remained unchanged at pH 8 5 f 1 0 At the lower 
pH range, enzyme actlvlty 1s higher for the rmmobrlrzed nzyme Dally oral admmrstratron of mrcroencapsu- 
lated phenylalanme ammonia-lyase to phenylketonurrc ats decreased the systemrc phenylalamne level by 
35 f 8% in 2 days (P < 0 05) and by 75 f 8% in 7 days (P < 0 001) 
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1. INTRODUCTION 
Artificial cells are semipermeable mrcrocapsules 
of cellular drmensrons wrth an ultrathm (200 A) 
membrane [l-3]. Enzymes rmmobrlized within ar- 
tificial cells can act effectively on permeant exter- 
nal substrates. Cells, antibodies, and proteolytic 
enzymes from the external environment are unable 
to come m direct contact with the microencap- 
sulated enzymes. Artificial cells have been suc- 
cessfully used for experimental enzyme replace- 
ment in acatalasemra, an inborn error of 
metabolism [3-61. In this case, the enzyme 
catalase, immobilized in artificial cells, was ad- 
ministered to acatalasemic rats via mtraperitoneal 
injections or extracorporeal shunts. Intravenous 
injectron of enzymes immobrhzed in liposomes has 
also been investigated for other types of ex- 
perimental enzyme replacement therapy [7]. In 
both approaches the need for parenteral mjections 
has delayed clinical apphcatrons because of the 
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potential accumulation of the injected material. 
The use of extracorporeal circulation or oral ad- 
ministration has been used to avoid these problems 
[3,6]. The special case of phenylketonurra (PKU) 1s 
Ideal for investigating the oral administration ap- 
proach. Artificial cells can be administered orally 
for substrate reduction in the gastrointestinal tract. 
Once rmmobilized within the artificial cells, the en- 
zyme is protected from proteolytic enzymes in the 
intestinal tract [3,6]. The artificial cells can act on 
phenylalanine from ingested food, as well as 
phenylalanme diffusing from the blood into the 
gastrointestinal tract. This approach has potential 
advantages in enzyme therapy when compared to 
earlier approaches in experimental enzyme 
therapy, based on parenteral injections or extra- 
corporeal errculation of blood. 
PKU is an inborn error of metabolism caused by 
a deficiency of the enzyme phenylalanine hydrox- 
ylase. This results in a deficiency in the conversron 
of phenylalamne to tyrosme, and m an increased 
level of phenylalanine and other metabohtes [8,9]. 
The high phenylalanme levels can be reduced by 
the use of a low phenylalanine diet. This diet 1s drf- 
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ficult to follow, however, and does not prevent 
rises m blood phenylalanine during episodes of 
fever and infection [lo]. A possible alternative to 
this diet is the use of enzyme therapy [ll]. 
However, there are problems related to the large 
scale isolation and purification of the enzyme 
phenylalanine hydroxylase from mammalian 
tissues. Furthermore, this enzyme requires co- 
factors [12]. PAL is another enzyme which con- 
verts phenylalanine, by deamination, into trans- 
cmnamic acid. This enzyme requires no co-factors 
and can be readily obtained from microbial 
sources [13]. PAL was therefore chosen for the 
present study. 
PAL was previously immobilized within 
semipermeable microcapsules by the standard 
method [3,6]. Previous in vitro studies carried out 
here have shown that mrcroencapsulated PAL acts 
effectively in the conversion of phenylalanine mto 
trans-cmnamic acid [ 141. Microencapsulated PAL 
has an apparent enzyme activity which 1s 20 ~fr 4% 
of the activity of the enzyme in free solution. The 
K,,, of the immoblhzed enzyme is not changed, 
whereas the V, is decreased. In order to test the 
feasibility of oral administration, further m vitro 
studies were carried out to study the pH optimum 
of the immobilized enzyme at pH values cor- 
responding to those along the gastrointestinal 
tract. These artificial cells were then tested in vivo 
on phenylketonuria-induced rats. 
2. MATERIALS AND METHODS 
2.1. Materials 
PAL from microbial source was purchased from 
P.L. Blochemicals. Collodion, bovine hemoglo- 
bin, L-phenylalanine, para-chlorophenylalanine 
methyl ester from Sigma, St. LOUIS, MO, tris- 
(hydroxymethyl)aminomethane, sodium acetate, 
succinic acid, potassium phosphate from Fisher, 
and 150-200 g male Sprague Dawley rats from 
Charles River Co. Distilled-deionized water was 
used throughout. 28.44 mg/ml PAL were suspend- 
ed in buffered 3.0 mM L-phenylalanine for assay- 
ing the enzyme activity. 
2.2. Instrumentation 
2.2.1. Spectrophotometer 
A Cary UV spectrophotometer (Cary 219) with 
6 
a deuterium lamp was employed to momtor the ab- 
sorption of trans-cinnamic acid in vitro at 290 nm 
and phenylalanme plasma level at 290 and 3 15 nm 
[151 
2.. 3. Methods 
2.3.1. PAL-loaded artificial cells 
5 units of PAL (spec. act. = 0.84 U/mg) were 
dissolved m 2.3 ml of a 10 g/d1 hemoglobin solu- 
tion. This was emulsified as described [3,6], then 
an ultrathin cellulose nitrate membrane (200 A 
thick) was formed around each mlcrodroplet 
(mean diameter of 150pm). 
2.3.2. pH activity profile 
The enzyme activity of artificial cells was studled 
using a stir-batch technique at various pH levels. 
The buffers used in the different pH ranges were as 
follows: pH 2-3 (0.1 M Trts-HCI), pH 4-5 
(0.1 M acetate), pH 6.0 (0.1 M succinate), pH 7.0 
(0.05 M phosphate) and pH 8-13 (0.1 M 
Tris-HCl). Aliquots were collected at timed mter- 
vals and levels of trans-cinnamrc actd analyzed by 
a standard technique [ 151. 
2.3.3. In vivo experiments 
In vivo experiments were performed on 150 g 
phenylketonuric male Sprague-Dawley rats. This 
phenylketonuric rat model was derived using slight 
modifications of methods previously described 
[16-181. Briefly, rats were given dally in- 
traperrtoneal inJections of L-phenylalanine (100 
mg/kg body wt) and DL-p-chlorophenylalanine 
methyl ester (300 mg/kg body wt). The following 
3 groups of rats were studied: (i) 3 normal control 
rats; (11) 10 control phenylketonuric rats were given 
orally 0.5 ml of control artificial cells containing 
hemoglobin but no enzyme, and (iii) 10 
phenylketonuric rats were given 0.5 ml of artificial 
cells containing 5 units (3.2 mg) of PAL. In both 
cases, artificial cells were administered orally at 
9.00 a.m. every day for 7 days. Daily blood 
samples, taken 6 h after the oral administration of 
the artificial cells, were collected from the tail vein. 
Blood phenylalanine levels were analysed using the 
established method of Shen and Abel1 [15] and 
used by workers in the field (Ambrus et al. [16]). 
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20-fold with all values being significant to the P < 
0.001 level. Daily oral administration of microen- 
capsulated PAL effectively reduced the systemic 
blood phenylalanine level of the treated 
phenylketonurtc rats. Compared to control PKU 
rats, the phenylalanine blood level was decreased 
to 65 f 8% on day 2 (P c 0.05), and to 25 & 8qo 
on day 7 (P < 0.001) (table 1). After 7 days of this 
form of enzyme therapy, systemic blood 
phenylalanine levels of the phenylketonuric rats 
had been lowered to a level which was not 
significantly different from those of the normal 
2 4 6 8 10 12 14 rats (P c d.10). Ambrus et al. [16] have reported 
pH a smaller decrease of blood phenylalanine usmg 
Ftg 1 pH vs acttvtty profile wtth all values expressed as PAL covalently linked to an extracorporeal shunt. 
means-k SD. Acttvtty of free enzyme in solution (b), Furthermore, their approach involves 
and tmmobthzed PAL m arttftctal cells (+) at extracorporeal blood circulatton. 
vartous pH values Here, the oral admintstratton of 
Table 1 
Phenylalamne plasma levels of normal, PKU control and PKU treated rats (mg/lOO ml) 
the use of 
PAL im- 
Days Normal PKU treated PKU control Stgnificance 
Student’s r-test 
treated vs normal 
Sigmficance 
Student’s t-test 
control vs treated 
0 (mmal) 16 4 + 8.0 25Ok 70 33 0 + 10.0 P<O50 P<O60 
2 41.3 + 20.6 339 7 k 28.8 522.1 Z!Z 70 2 P < 0.001 P<OO5 
4 41.3 f 28 9 251.2 k 30.2 468 2 f 44.0 P<OOOl P<OOOl 
7 33 6 f 29.3 82 7 k 7.0 331.4 f 26.4 P<OlO P<Oool 
Values are means + SE 
3. RESULTS AND DISCUSSION 
Results of the pH activity profile are shown m 
fig. 1. The microencapsulated enzyme was more ac- 
tive than the free enzyme at lower pH values. This 
is probably due to the buffermg capacity of 
hemoglobm within the artificial cells, as well as the 
effect of the high concentration of hemoglobin in 
stabilizing the enzyme. Results showed that the op- 
timal pH for free enzyme m solution and enzyme 
immobilized m artificial cells were both at pH 
8.5 + 1 .O (fig. 1). The pH optimum corresponds to 
the average pH range of the small intestine. The m 
vivo results indicate that the phenylalanme blood 
levels were significantly increased in control 
phenylketonuric rats compared to normal control 
rats. This sustained increase varied from 15- to 
mobilized within artificial cells was significantly 
more effective m lowering systemic phenylalanine 
level without the need for extracorporeal blood cir- 
culation or parenteral inJections. 
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